Gene Expression in Human Chondrocytes in Late Osteoarthritis is Changed in Both Fibrillated and Intact Cartilage Without Evidence of Generalised Chondrocyte Hypertrophy
Overview
Affiliations
Objectives: To investigate changes in gene expression in fibrillated and intact human osteoarthritis (OA) cartilage for evidence of an altered chondrocyte phenotype and hypertrophy.
Methods: Paired osteochondral samples were taken from a high-load site and a low-load site from 25 OA joints and were compared with eight similar paired samples from age-matched controls. Gene expression of key matrix and regulatory genes was analysed by quantitative real-time reverse transcription-polymerase chain reaction on total RNA extracted from the cartilage.
Results: There was a major change in chondrocyte gene expression in OA cartilage. SOX9 (38-fold) and aggrecan (4-fold) gene expression were both lower in OA (p<0.001), and collagen I (17-fold) and II (2.5-fold) gene expression were each increased in a subset of OA samples. The major changes in gene expression were similar at the fibrillated high-loaded site and the intact low-loaded site. There was no evidence of a generalised change in OA to proliferative or hypertrophic phenotype as seen in the growth plate, as genes associated with either stage of differentiation were unchanged (PTHrPR), or significantly downregulated (collagen X (14-fold, p<0.002), VEGF (23-fold, p<0.02), BCL-2 (5.6-fold, p<0.001), matrilin-1 (6.5-fold, p<0.001)). In contrast MMP-13 was significantly upregulated in the OA cartilage samples (5.3-fold, p<0.003).
Conclusions: The expression of key chondrocyte genes, including aggrecan and SOX9, was decreased in OA cartilage and the changes were similar in both fibrillated high-loaded and intact low-loaded cartilage on the same joint. However, there was no significant upregulation of type X collagen, and other genes associated with chondrocyte further differentiation and hypertrophy.
Li M, Deng T, Chen Q, Jiang S, Li H, Li J Bioact Mater. 2025; 47:100-120.
PMID: 39897588 PMC: 11787566. DOI: 10.1016/j.bioactmat.2025.01.011.
FTO-mediated SMAD2 m6A modification protects cartilage against Osteoarthritis.
Zhou H, Xie Z, Qian Y, Ni W, Cui L, Fang X Exp Mol Med. 2024; 56(10):2283-2295.
PMID: 39363112 PMC: 11542000. DOI: 10.1038/s12276-024-01330-y.
Articular cartilage corefucosylation regulates tissue resilience in osteoarthritis.
Homan K, Onodera T, Hanamatsu H, Furukawa J, Momma D, Matsuoka M Elife. 2024; 12.
PMID: 38466626 PMC: 10928514. DOI: 10.7554/eLife.92275.
Poulsen R, Jain L, Dalbeth N Arthritis Res Ther. 2023; 25(1):59.
PMID: 37046337 PMC: 10100340. DOI: 10.1186/s13075-023-03042-6.
Ranmuthu C, Ranmuthu C, Wijewardena C, Seah M, Khan W Int J Mol Sci. 2022; 23(23).
PMID: 36499531 PMC: 9741425. DOI: 10.3390/ijms232315210.